• Neuroendocrine Tumors (NETs) are tumours originated from the hormone-producing cells or nerve cells (the neuroendocrine system). (qtinstruments.com)
  • The results of the phase III NETTER-1 trial, recently published in The New England Journal of Medicine, 1 have been met with great interest by clinicians who treat neuroendocrine tumors. (ascopost.com)
  • At the 2017 Gastrointestinal Cancers Symposium, principal investigator of NETTER-1, Jonathan Strosberg, MD , of Moffitt Cancer Center in Tampa, Florida, brought listeners up-to-date on this effective second-line therapy and looked ahead to future treatments of neuroendocrine tumors. (ascopost.com)
  • The study randomized 229 patients with well-differentiated metastatic or locally advanced inoperable midgut neuroendocrine tumors to receive 4 intravenous administrations (every 8 weeks) of the peptide receptor radionuclide therapy (plus best supportive care, including standard-dose octreotide long-acting repeatable [LAR]) or high-dose octreotide LAR alone. (ascopost.com)
  • In a large multi-institutional German study, the newer agent almost doubled the progression-free survival time over 90-Y dotatate and improved overall survival at 4 years from about 40% to approximately 70%, with the greatest effect seen in small bowel neuroendocrine tumors. (ascopost.com)
  • As both speakers indicated, peptide receptor radionuclide therapy (90-Y dotatate or Lu-177 dotatate ) is recommended for patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors that are progressing despite standard-dose long-acting somatostatin analog therapy and for pancreatic neuroendocrine tumors progressing after somatostatin analog therapy or everolimus (Afinitor). (ascopost.com)
  • First line treatment with Lutathera in combination with long-acting octreotide demonstrated a significant improvement in progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose long-acting octreotide alone 1,2 . (novartis.com)
  • The approval of Lutathera was originally based on the pivotal NETTER-1 trial, which demonstrated highly significant and clinically meaningful PFS prolongation for patients treated with Lutathera in combination with long-acting octreotide versus high-dose (60 mg) long-acting octreotide for SSTR-positive, inoperable midgut neuroendocrine tumors (NETs) who were progressing despite standard treatment 3-4,9 . (novartis.com)
  • Lutathera ® (INN: lutetium ( 177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) is an Advanced Accelerator Applications RLT approved in the United States for the treatment of SSTR-positive GEP-NETs, including foregut, midgut and hindgut neuroendocrine tumors in adults and in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults 1 0 - 1 1 . (novartis.com)
  • Neuroendocrine neoplasms (NENs) include all tumors derived from the diffuse endocrine system. (springeropen.com)
  • This was necessary for the production of the now registered Lutetium-177-Dotatate. (advancingnuclearmedicine.com)
  • This follows a very positive year - in September, the Company received EU approval of Lutathera ® (lutetium-177 dotatate) for Gastroenteropancreatic Neuroendocrine tumours. (biospace.com)
  • In patients with advanced midgut lesions, treatment with the radiopharmaceutical lutetium Lu-177 dotatate (Lutathera) led to markedly longer progression-free survival and significantly higher response rates vs the control arm. (ascopost.com)
  • Lu-177 dotatate , a peptide receptor radionuclide therapy, consists of the somatostatin analog octreotate connected with the beta- and gamma-emitting radiopharmaceutical lutetium-177. (ascopost.com)
  • Basel, September 25, 2023 - Today, Novartis announced the Phase III NETTER-2 trial with Lutathera ® (INN: lutetium ( 177 Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) met its primary endpoint. (novartis.com)
  • Lutetium occurs on the Earth in form of two isotopes: lutetium-175 and lutetium-176. (wikipedia.org)
  • the most stable such isotopes are lutetium-174 with a half-life of 3.31 years, and lutetium-173 with a half-life of 1.37 years. (wikipedia.org)
  • As we look to the future, innovations in medical isotopes are providing a pathway for researchers and healthcare professionals to improve lives through targeted cancer therapies. (brucepower.com)
  • However, instead of labelling the PSMA-ligands with imaging isotopes like Ga-68 or Fluorine-18, it is labelled with therapeutic isotopes such as Lutetium-177 (Lu-177) or Actinium-225 (Ac-225). (qtinstruments.com)
  • This was a critical step to enable the production of Lutetium-177 for our partner, ITM, and to fortifying a strong, reliable, and large-scale global supply chain of life-saving isotopes, that both physicians and patients can depend on. (nawash.ca)
  • Lutetium-177 is used in precision oncology for targeted therapy of a growing number of cancers, including neuroendocrine tumours and prostate cancer. (brucepower.com)
  • As PSMA is highly expressed in over 90% of prostate cancers, researchers have designed imaging ligands that would bind to PSMA in the body. (qtinstruments.com)
  • Lu-177 is a medical isotope used in the treatment of various cancers, such as neuroendocrine tumours and prostate cancer. (nawash.ca)
  • When two radioactive drugs are used together to diagnose and treat diseases, they are called theranostics and are typically used in this manner as a result from Ga-68 being used to scan and in certain cases diagnose patients with Neuroendocrine Tumours (NETs). (ukessays.com)
  • NETs are a type of cancer that originate in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies. (novartis.com)
  • Lutetium-176 is a relatively abundant (2.5%) radioactive isotope with a half-life of about 38 billion years, used to determine the age of minerals and meteorites. (wikipedia.org)
  • A number of Dutch UMC's have been involved with clinical tests that are evaluating the effect of radioactive lutetium-177 n.c.a. in the treatment of metastatic kidney cancer. (advancingnuclearmedicine.com)
  • To achieve the cytotoxic effect necessary to destroy tumour cells, radioactive dose administered is higher compared to diagnostic imaging. (qtinstruments.com)
  • For instance, in cancer treatment, the molecule might be designed to bind to cancer cells, allowing the radioactive copper to be delivered directly to the tumour site. (openmedscience.com)
  • An example of a promising treatment currently under investigation is lutetium-177-PSMA for treatment in patients with metastatic castration-resistant prostate cancer. (advancingnuclearmedicine.com)
  • [ 3 ] Ductal carcinoma and neuroendocrine carcinoma account for the majority of additional cases. (medscape.com)
  • The second group includes large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC). (springeropen.com)
  • Bruce Power and Isogen (a partnership between Kinectrics and Framatome) have completed the installation of a groundbreaking Isotope Production System (IPS), making Unit 7 the first power reactor in the world with installed capability to produce Lutetium-177 (Lu-177). (nawash.ca)
  • From the very beginning that nuclear medicine started looking into using lutetium for therapeutic purposes, NRG has been involved as important irradiator of this isotope. (advancingnuclearmedicine.com)
  • Lutetium-177 is a very versatile isotope, and worldwide numerous clinical trials are being held, studying the effects of this isotope. (advancingnuclearmedicine.com)
  • Researchers have found numerous possible applications for this radio isotope. (advancingnuclearmedicine.com)
  • Bruce Power is the first commercial nuclear power reactor in the world to produce lutetium-177, a short-lived medical isotope, using a first-of-a-kind Isotope Production System (IPS). (brucepower.com)
  • Lutetium-177, as well as the global supply of n.c.a. 177 Lu, will be handled by ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company that is one of the largest and most reliable producer of Lu-177 for pharmaceutical use. (nawash.ca)
  • 177Lu-DOTA-TATE is used for radionuclide therapy (see Nuclear medicine) on neuroendocrine tumours. (wikipedia.org)
  • Lutetium-177 is produced through 2 primary methods, the direct way, and the indirect way and both include the process of Neutron bombardment which enacts the process of nuclear fission. (ukessays.com)
  • Such images provide very useful tumour localization information that will allow clinicians to perform more accurate treatment plan, ensuring the right treatment is given to the right patient at the right stage of the disease. (qtinstruments.com)
  • This property allows for high-resolution imaging, enabling clinicians to visualise and diagnose various conditions accurately, especially in oncology, where precise tumour localisation is critical. (openmedscience.com)
  • As it's a difficult disease to diagnose, many people struggle with these syndromes for some time before formal diagnosis of Neuroendocrine Cancer. (ronnyallan.net)
  • Lutetium was independently discovered in 1907 by French scientist Georges Urbain, Austrian mineralogist Baron Carl Auer von Welsbach, and American chemist Charles James. (wikipedia.org)
  • Two researchers independently undertook the technical review in October 2021. (bvsalud.org)
  • Lutetium-177 (Lu-177) and Gallium 68 (Ga-68) have both seen major uses in the medical industry in the last decade and can be commonly seen in usage together. (ukessays.com)
  • In 2017, the EMA approved Lu-177-Dotate (based on Lu-177 c.a.), which can be used to treat this type of tumour. (advancingnuclearmedicine.com)
  • As there are significant advantages to no-carrier added lutetium-177, additional solutions are being developed and tested to treat NET tumours. (advancingnuclearmedicine.com)
  • How effective is Luteium-177 and Gallium-68 as theranostics to treat neuroendocrine tumours? (ukessays.com)
  • Each combination of pillar and type of research is coordinated by a dedicated physician/researcher, as can be seen in the structured overview of the Dosimetry Core Unit. (radboudumc.nl)
  • Aqueous solutions of most lutetium salts are colorless and form white crystalline solids upon drying, with the common exception of the iodide, which is brown. (wikipedia.org)
  • Lutetium dissolves readily in weak acids and dilute sulfuric acid to form solutions containing the colorless lutetium ions, which are coordinated by between seven and nine water molecules, the average being [Lu(H2O)8.2]3+. (wikipedia.org)
  • Solutions with lutetium-177 chloride (n.c.a. (advancingnuclearmedicine.com)
  • We summarize two key issues arising, and we set out proposed changes to the search interface, including: adding the ability to export abstracts to a bibliographic tool, exporting search strategies, adding a researcher account, and updating the help guide. (bvsalud.org)
  • With its new IPS system, Bruce Power will conduct the irradiation of Ytterbium-176 ( 176 Yb) as a first step in the production of no-carrier-added Lutetium-177 (n.c.a. 177 Lu). (nawash.ca)
  • All of these researchers found lutetium as an impurity in the mineral ytterbia, which was previously thought to consist entirely of ytterbium. (wikipedia.org)
  • 2 Lu + 3 H2SO4 → 2 Lu3+ + 3 SO2−4 + 3 H2↑ Lutetium is usually found in the +3 oxidation state, like most other lanthanides. (wikipedia.org)
  • Lutetium metal is slightly unstable in air at standard conditions, but it burns readily at 150 °C to form lutetium oxide. (wikipedia.org)